These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 19394403)

  • 1. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.
    Schwarcz R; Guidetti P; Sathyasaikumar KV; Muchowski PJ
    Prog Neurobiol; 2010 Feb; 90(2):230-45. PubMed ID: 19394403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
    Perez-De La Cruz V; Santamaria A
    Physiol Res; 2007; 56(5):513-526. PubMed ID: 17184144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
    Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drosophila eye color mutants as therapeutic tools for Huntington disease.
    Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
    Guidetti P; Schwarcz R
    Adv Exp Med Biol; 2003; 527():137-45. PubMed ID: 15206726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
    Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
    Mazarei G; Leavitt BR
    J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
    Guidetti P; Reddy PH; Tagle DA; Schwarcz R
    Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitotoxic neuronal death and the pathogenesis of Huntington's disease.
    Estrada Sánchez AM; Mejía-Toiber J; Massieu L
    Arch Med Res; 2008 Apr; 39(3):265-76. PubMed ID: 18279698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
    Front Immunol; 2022; 13():997240. PubMed ID: 36263032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
    Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
    Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generating Excitotoxic Lesion Models of Huntington's Disease.
    Lelos MJ; Dunnett SB
    Methods Mol Biol; 2018; 1780():209-220. PubMed ID: 29856021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
    Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H
    Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
    Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
    Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.